Alpha 2.0
Login Register
» Authors » Anna Bulfamante

Anna Bulfamante

Explore the profile of Anna Bulfamante including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 45
Followers 0
Related Specialties
General Medicine
Pediatrics
Science
Top 10 Co-Authors
Carla Colombo
Maria Garriga
Joaquim Calvo-Lerma
Etna Masip
Mieke Boon
Kris De Boeck
Carmen Ribes-Koninckx
Jessie Hulst
Ine Claes
Maria Roca
Published In
PLoS One
J Cyst Fibros
Arch Dis Child
J Acad Nutr Diet
Nutrients
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-term evaluation of faecal calprotectin levels in a European cohort of children with cystic fibrosis
Roca M, Masip E, Colombo C, Boon M, Hulst J, Garriga M, et al.
Arch Dis Child . 2023 Dec; 109(7):552-556. PMID: 38123920
Objective: Intestinal inflammation with contradictory data on faecal calprotectin (fCP) levels is documented in patients with cystic fibrosis (CF). The aim of this study was to longitudinally evaluate fCP in...
2.
Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study
Zazzeron L, Alicandro G, Dacco V, Lanfranchi C, Bulfamante A, Sciarrabba C, et al.
Dig Liver Dis . 2022 Oct; 55(3):360-365. PMID: 36253246
Background: Evidence on the effectiveness of proton pump inhibitors (PPI) as adjuvant therapy to improve maldigestion in people with cystic fibrosis (pwCF) is limited and there is increasing concern on...
3.
Change in Nutrient and Dietary Intake in European Children with Cystic Fibrosis after a 6-Month Intervention with a Self-Management mHealth Tool
Calvo-Lerma J, Boon M, Hulst J, Colombo C, Asseiceira I, Garriga M, et al.
Nutrients . 2021 Jun; 13(6). PMID: 34073260
Cystic Fibrosis (CF) is a life-long genetic disease, causing increased energy needs and a healthy diet with a specific nutrient distribution. Nutritional status is an indicator of disease prognosis and...
4.
Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis
Calvo-Lerma J, Boon M, Colombo C, De Koning B, Asseiceira I, Garriga M, et al.
J Cyst Fibros . 2020 Dec; 20(5):e33-e39. PMID: 33279468
Background: Patients with cystic fibrosis (CF) and pancreatic insufficiency need pancreatic enzyme replacement therapy (PERT) for dietary lipids digestion. There is limited evidence for recommending the adequate PERT dose for...
5.
Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose
Calvo-Lerma J, Roca M, Boon M, Colombo C, De Koning B, Fornes-Ferrer V, et al.
Pediatr Res . 2020 Apr; 89(1):205-210. PMID: 32247283
Background: Despite treatment with pancreatic enzyme replacement therapy (PERT), patients with cystic fibrosis (CF) can still suffer from fat malabsorption. A cause could be low intestinal pH disabling PERT. The...
6.
Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
Boon M, Claes I, Havermans T, Fornes-Ferrer V, Calvo-Lerma J, Asseiceira I, et al.
PLoS One . 2019 Dec; 14(12):e0225004. PMID: 31860639
Background: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related...
7.
The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment
Calvo-Lerma J, Hulst J, Boon M, Martins T, Ruperto M, Colombo C, et al.
J Acad Nutr Diet . 2019 Mar; 119(8):1305-1319. PMID: 30862484
Background: Optimal nutrition for children with cystic fibrosis (CF) improves prognosis and survival, but an increased caloric intake recommendation for this population raises concerns about the nutrient profile of their...
8.
Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis
Calvo-Lerma J, Hulst J, Boon M, Colombo C, Masip E, Ruperto M, et al.
PLoS One . 2019 Mar; 14(3):e0213216. PMID: 30861039
Background: A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. Objectives: To assess the in vivo efficacy of a method to adjust the dose...